Ahad Abdul, Raish Mohammad, Al-Jenoobi Fahad I, Al-Mohizea Abdullah M
Department of Pharmaceutics, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia.
Curr Drug Deliv. 2018 Feb 14;15(2):260-266. doi: 10.2174/1567201814666170518131934.
Niosomes are non-ionic surfactant vesicles used as drug carriers for encapsulating both hydrophobic and hydrophilic drugs. The aim of the present study was to prepare and characterize niosomes formulations for oral delivery of telmisartan and evaluated for its antihypertensive activity.
Telmisartan loaded niosomes were prepared using thin film hydration method by varying the Span 60 and cholesterol at several molar ratios and characterized for vesicles size, polydispersity index, zeta potential, entrapment efficiency. The in vivo antihypertensive study of optimized formulation and molecular impact of angiotensin II type-1 receptor (AT1R) messenger Ribonucleic acid (mRNA) and protein expression on smooth vascular muscles of aorta was determined by real-time polymerase chain reaction (RT-PCR) and western blot analysis in Wistar albino rats.
The optimized niosomes formulation NS6 presented vesicles size of 618.47 nm, polydispersity index of 0.86, with entrapment efficiency of 83.83% and possesses negative charge. In vivo study showed that the optimized formulation could reduce the systolic blood pressure in methyl prednisolone acetate induced hypertensive rats in close proximity to normal range of systolic blood pressure and maintain it over an extended period. In addition, telmisartan loaded niosomes treatment to hypertensive rats significantly attenuates the raised mRNA level and protein level of AT1R gene in comparison to hypertensive rats.
Results of present study confer the potential of developed niosomes as suitable carriers for improved oral delivery of telmisartan.
非离子表面活性剂囊泡用作药物载体,可包封疏水性和亲水性药物。本研究的目的是制备用于替米沙坦口服给药的非离子表面活性剂囊泡制剂,并对其进行表征,同时评估其降压活性。
采用薄膜水化法,通过改变司盘60和胆固醇的摩尔比制备载替米沙坦的非离子表面活性剂囊泡,并对囊泡大小、多分散指数、zeta电位、包封率进行表征。通过实时聚合酶链反应(RT-PCR)和蛋白质免疫印迹分析,在Wistar白化大鼠中测定优化制剂的体内降压研究以及血管紧张素II 1型受体(AT1R)信使核糖核酸(mRNA)和蛋白表达对主动脉平滑肌的分子影响。
优化后的非离子表面活性剂囊泡制剂NS6的囊泡大小为618.47 nm,多分散指数为0.86,包封率为83.83%,且带负电荷。体内研究表明,优化后的制剂可使醋酸甲基泼尼松龙诱导的高血压大鼠的收缩压降低至接近正常收缩压范围,并在较长时间内维持该水平。此外,与高血压大鼠相比,给高血压大鼠用载替米沙坦的非离子表面活性剂囊泡治疗可显著降低AT1R基因升高的mRNA水平和蛋白水平。
本研究结果表明,所开发的非离子表面活性剂囊泡有潜力作为合适的载体,用于改善替米沙坦的口服给药。